| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 25 -> 34 locations |
| 2026-06-09 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 20 -> 25 locations |
| 2026-05-30 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 13 -> 20 locations |
| 2026-05-28 | NCT07428616 A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma |
Recruitment opened |
| 2026-05-27 | NCT07489495 A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… |
Trial sites expanded: 8 -> 13 locations |
| 2026-05-19 | NCT07428616 A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma |
Trial sites expanded: 0 -> 3 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-03 | NCT07623460 Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration… | Phase 2 | Not Yet Recruiting |
| 2026-06-02 | NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Phase 3 | Not Yet Recruiting |
| 2026-05-27 | NCT07608718 Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate… | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer… | Renal Cell Carcinoma | Recruiting |
| NCT07489495 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell… | Carcinoma, Renal Cell | Recruiting |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… | Cancer | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT06943755 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic… | Pancreatic Neuroendocrine Tumor (pNET) | Recruiting |
| Phase 2 | |||
| NCT06571734 | XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable… | Metastatic Leiomyosarcoma | Recruiting |
| NCT07193550 | A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE) | Bone Sarcomas | Recruiting |
| NCT07283731 | Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of… | Phase 2 | Recruiting |
| NCT06863311 | Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress… | Advanced Renal Cell Carcinoma | Recruiting |
| NCT06959641 | XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory… | Locally Advanced Differentiated Thyroid Gland Carcinoma | Recruiting |
| NCT07428616 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma | Meningioma | Recruiting |
| NCT06959511 | Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery | Neoadjuvant Treatment | Recruiting |
| NCT06794229 | Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or… | Locally Advanced Renal Cell Carcinoma | Recruiting |
| NCT07511504 | Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of… | Locally Advanced Hepatocellular Carcinoma | Not Yet Recruiting |
| NCT07527169 | A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory… | Metastatic Olfactory Neuroblastoma | Not Yet Recruiting |
| NCT07470489 | Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid… | Anaplastic Thyroid Cancer | Not Yet Recruiting |
| NCT07043608 | Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases | Clear Cell Renal Cell Cancer (ccRCC) | Not Yet Recruiting |
| NCT07226063 | Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular… | Hepatocellular Carcinoma | Not Yet Recruiting |
| NCT07484139 | H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in… | Oral Cavity Squamous Cell Carcinoma | Not Yet Recruiting |
| NCT07578025 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After… | Metastatic Clear Cell Renal Cell Carcinoma | Not Yet Recruiting |
| NCT07185945 | Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy | Advanced Urothelial Carcinoma | Not Yet Recruiting |
| NCT07608718 | Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate… | Metastatic Castration-resistant Prostate Cancer | Not Yet Recruiting |
| NCT07623460 | Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration… | mCRPC (Metastatic Castration-resistant Prostate Cancer) | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT07049926 | Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma… | Renal Cell Carcinoma | Recruiting |
| Phase 1 | |||
| NCT06968988 | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic… | Metastatic Soft-tissue Sarcoma | Recruiting |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With… | Renal Cell Carcinoma (RCC) | Recruiting |